Protein detail
KCNT1
Potassium channel subfamily T member 1 (KCa4.1) (KNa1.1) (Sodium and chloride-activated ATP-sensitive potassium channel Slo2.2)
Entry name KCNT1 | UniProt ID | EVMP score 0.50 |
Frequency 1 | Transmembrane count 6 | Protein classification Disease related genesHuman disease related genesPotential drug targetsPredicted membrane proteinsTransportersVoltage-gated ion channels |
EVMP score: annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
Basic Information
Protein Names
Potassium channel subfamily T member 1 (KCa4.1) (KNa1.1) (Sodium and chloride-activated ATP-sensitive potassium channel Slo2.2)
Protein Class
Disease related genesHuman disease related genesPotential drug targetsPredicted membrane proteinsTransportersVoltage-gated ion channels
Protein Function
- Human disease related genes:Nervous system diseases:Epilepsy
- Potential drug targets
- Voltage-gated ion channels:Calcium-Activated Potassium Channels
- Transporters:Transporter channels and pores
- Disease related genes
Transmembrane
94..126; Helical; Name=Segment S1; 154..178; Helical; Name=Segment S2; 193..208; Helical; Name=Segment S3; 216..233; Helical; Name=Segment S4; 247..274; Helical; Name=Segment S5; 305..338; Helical; Name=Segment S6
Transmembrane Count
6
Ensembl
Entrez Gene Symbol
Gene Synonym
KCa4.1KIAA1422SLACKSlo2.2
Gene Description
Potassium sodium-activated channel subfamily T member 1
Chromosome
9
Position
135702185-135795508
Frequency
1
EVMP Score
0.50
Fluorescence & Localization
Cell SpecificExtravillous trophoblastsSingle-Nuclei Brain Specificendothelial cellBlood Cell SpecificMAIT T-cellBlood Lineage SpecificT-cellsSecretome LocationSecreted to bloodSecretome FunctionReceptor
Function & Pathway
Protein Function
- Human disease related genes:Nervous system diseases:Epilepsy
- Potential drug targets
- Voltage-gated ion channels:Calcium-Activated Potassium Channels
- Transporters:Transporter channels and pores
- Disease related genes
Cellular Component
Molecular Function
Biological Process
Canonical Pathways
M159 Pid amb2 neutrophils pathway
Mediation Categories
Clinical-translation mediationFusion and delivery mediation
Relations & Evidence
Enzyme-Mediated Modification
0 records.
Ligand-Receptor Signaling
17 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| transmembrane | transmembrane | OmniPath | No | No | No | No | No |
| peripheral | peripheral | UniProt_topology | No | No | No | No | No |
| peripheral | peripheral | OmniPath | No | No | No | No | No |
| plasma_membrane | plasma_membrane | UniProt_location | No | No | No | No | No |
| plasma_membrane | plasma_membrane | OmniPath | No | No | No | No | No |
| receptor | receptor | scConnect | No | Yes | No | No | No |
| transmembrane | transmembrane_predicted | Phobius | No | No | No | No | No |
Page 2 of 2Previous
Regulatory Interaction Network
0 records.
Protein Complex Composition
Isolation & Detection Technology
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential Ultracentrifugation | Mass spectrometry | 1 | 28986585 |
Sequence, Structure & Domains
Sequences
Length
1,230
Mass
138,343
Sequence
MARAKLPRSPSEGKAGPGGAPAGAAAPEEPHGLSPLLPARGGGSVGSDVGQRLPVEDFSLDSSLSQVQVEFYVNENTFKERLKLFFIKNQRSSLRIRLFNFSLKLLTCLLYIVRVLLDDPALGIGCWGCPKQNYSFNDSSSEINWAPILWVERKMTLWAIQVIVAIISFLETMLLIYLSYKGNIWEQIFRVSFVLEMINTLPFIITIFWPPLRNLFIPVFLNCWLAKHALENMINDFHRAILRTQSAMFNQVLILFCTLLCLVFTGTCGIQHLERAGENLSLLTSFYFCIVTFSTVGYGDVTPKIWPSQLLVVIMICVALVVLPLQFEELVYLWMERQKSGGNYSRHRAQTEKHVVLCVSSLKIDLLMDFLNEFYAHPRLQDYYVVILCPTEMDVQVRRVLQIPLWSQRVIYLQGSALKDQDLMRAKMDNGEACFILSSRNEVDRTAADHQTILRAWAVKDFAPNCPLYVQILKPENKFHVKFADHVVCEEECKYAMLALNCICPATSTLITLLVHTSRGQEGQESPEQWQRMYGRCSGNEVYHIRMGDSKFFREYEGKSFTYAAFHAHKKYGVCLIGLKREDNKSILLNPGPRHILAASDTCFYINITKEENSAFIFKQEEKRKKRAFSGQGLHEGPARLPVHSIIASMGTVAMDLQGTEHRPTQSGGGGGGSKLALPTENGSGSRRPSIAPVLELADSSALLPCDLLSDQSEDEVTPSDDEGLSVVEYVKGYPPNSPYIGSSPTLCHLLPVKAPFCCLRLDKGCKHNSYEDAKAYGFKNKLIIVSAETAGNGLYNFIVPLRAYYRSRKELNPIVLLLDNKPDHHFLEAICCFPMVYYMEGSVDNLDSLLQCGIIYADNLVVVDKESTMSAEEDYMADAKTIVNVQTMFRLFPSLSITTELTHPSNMRFMQFRAKDSYSLALSKLEKRERENGSNLAFMFRLPFAAGRVFSISMLDTLLYQSFVKDYMITITRLLLGLDTTPGSGYLCAMKITEGDLWIRTYGRLFQKLCSSSAEIPIGIYRTESHVFSTSESQISVNVEDCEDTREVKGPWGSRAGTGGSSQGRHTGGGDPAEHPLLRRKSLQWARRLSRKAPKQAGRAAAAEWISQQRLSLYRRSERQELSELVKNRMKHLGLPTTGYEDVANLTASDVMNRVNLGYLQDEMNDHQNTLSYVLINPPPDTRLEPSDIVYLIRSDPLAHVASSSQSRKSSCSHKLSSCNPETRDETQL
Alternative Products
Event=Alternative splicing; Named isoforms=4; Name=1; IsoId=Q5JUK3-1; Sequence=Displayed; Name=2; IsoId=Q5JUK3-2; Sequence=VSP_015470, VSP_015471; Name=3; IsoId=Q5JUK3-3; Sequence=VSP_015470, VSP_015471, VSP_044476; Name=4; IsoId=Q5JUK3-4; Sequence=VSP_055700, VSP_055701, VSP_015471
Alternative Sequence
1..66; MARAKLPRSPSEGKAGPGGAPAGAAAPEEPHGLSPLLPARGGGSVGSDVGQRLPVEDFSLDSSLSQ -> MPLPDGARTPGGVCREARGGGYTNRTFEFDDGQCAPRRPCAGDGALLDTAGFKMSDLDSEVLPLPPRYRFRDLLLGDPSFQNDDR (in isoform 2 and isoform 3); 1..66; MARAKLPRSPSEGKAGPGGAPAGAAAPEEPHGLSPLLPARGGGSVGSDVGQRLPVEDFSLDSSLSQ -> MPLPDGARTPGGVCREARGGGYTNRTFEFDDGQCAPR (in isoform 4); 266; G -> GGCR (in isoform 4); 1033; E -> EPHDLRAQ (in isoform 2, isoform 3 and isoform 4); 1142..1162; Missing (in isoform 3)
3D Structural Models
Turn
187..189; 274..278; 522..525; 551..553; 611..614; 963..965
Helix
72..75; 78..86; 92..116; 120..122; 146..149; 155..178; 193..208; 211..214; 219..221; 222..234; 249..273; 282..293; 306..337; 346..352; 364..374; 378..380; 395..402; 404..407; 420..425; 428..430; 445..462; 475..480; 490..503; 507..514; 529..537; 554..556; 561..572; 615..624; 757..760; 774..777; 793..803; 809..811; 825..831; 847..853; 855..857; 868..871; 875..879; 880..892; 905..910; 918..932; 939..941; 943..946; 954..962; 969..976; 995..997; 1003..1013; 1103..1116; 1119..1134
Beta Strand
124..129; 138..140; 184..186; 299..301; 354..358; 384..388; 410..413; 434..437; 440..443; 464..466; 468..474; 484..489; 541..547; 575..580; 587..589; 602..609; 731..733; 748..750; 761..764; 783..790; 815..821; 837..841; 844..846; 858..863; 897..903; 949..952; 987..993; 1017..1026; 1171..1178; 1189..1195
3D Structure
Electron microscopy (6)
Domain & Motif Annotations
Compositional Bias
1057..1072; Gly residues; 1204..1219; Low complexity
Domain (CC)
The cytoplasmic gating ring domain of the closed KCNT1 channel harbors multiple K(+) and Zn(2+) sites, which stabilize the channel in the closed conformation. Under low-Na(+) conditions, the abundant cytoplasmic K(+) ions stabilize the gating ring domain in a closed conformation. KCNT1 contains at least two Na(+)-sensitive sites in the RCKs domain where Na(+) binding induces expansion and rotation of the gating ring that opens the inner gate.; DOMAIN: The cytoplasmic N-terminal domain facilitates the localization of heteromeric KCNT1/KCNT2 channels to the plasma membrane.
Domain (FT)
352..488; RCK N-terminal 1; 781..921; RCK N-terminal 2
Region
1..37; Disordered; 660..689; Disordered; 1048..1078; Disordered; 1204..1230; Disordered
Protein Families
- Potassium channel family
- Calcium-activated (TC 1.A.1.3) subfamily
- KCa4.1/KCNT1 sub-subfamily
Sequence Similarities
Belongs to the potassium channel family. Calcium-activated (TC 1.A.1.3) subfamily. KCa4.1/KCNT1 sub-subfamily.
Clinical Relevance
Disease Involvement
Disease variantEpilepsy
Related Diseases
Biomarker
Phase 2